Nintedanib Accord (Nintedanib)

Nintedanib blocks multiple receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—thereby reducing fibroblast activation, new blood‑vessel formation, and extracellular matrix production. This inhibition curtails the processes that lead to tissue scarring in the lungs and limits tumor‑driven angiogenesis in cancer.

The specific dose and dosing schedule of Nintedanib Accord are determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and concomitant medications. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

The safety of Nintedanib Accord in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with pirfenidone, another antifibrotic approved for idiopathic pulmonary fibrosis, nintedanib targets a broader range of tyrosine kinases, offering a different mechanism of action. Clinical studies suggest comparable efficacy in slowing lung‑function decline, but side‑effect profiles differ, with nintedanib more frequently causing gastrointestinal symptoms.

Nintedanib Accord should be stored at temperatures below 25 °C (77 °F). Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and store them out of reach of children. Do not refrigerate or freeze the product.

Nintedanib Accord is taken orally, usually with food to reduce gastrointestinal upset. The tablets are swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their healthcare professional and not alter the schedule without medical advice.

Serious risks include significant liver enzyme elevations that may indicate hepatic injury, severe bleeding events especially when combined with anticoagulants, cardiovascular complications such as hypertension or arterial thromboembolism, and rare but life‑threatening gastrointestinal perforations. Patients should be monitored closely for these events.

Nintedanib Accord is contraindicated in patients with known hypersensitivity to nintedanib or any of its excipients. It should be used with caution, or avoided, in individuals with severe hepatic impairment, active bleeding disorders, uncontrolled hypertension, or those who are pregnant or breastfeeding without a clear benefit.